Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
$4.88
-3.4%
$4.45
$1.31
▼
$9.30
$12.80M1.535,640 shs83,319 shs
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
$1.13
+6.6%
$1.38
$0.90
▼
$7.04
$43.20M2.0879,255 shs69,285 shs
InterCure Ltd. stock logo
INCR
InterCure
$3.60
-0.8%
$4.69
$3.12
▼
$7.55
$39.38M1.513,942 shs2,362 shs
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$14.50
-6.8%
$14.09
$5.75
▼
$23.30
$48.00M0.9469,753 shs26,981 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
0.00%0.00%+39.71%-10.53%-40.01%
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-4.50%-11.67%-13.11%-50.47%-80.97%
InterCure Ltd. stock logo
INCR
InterCure
-4.35%-0.14%-20.68%-23.92%-47.08%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.00%0.00%+9.85%+0.69%-14.96%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
$4.88
-3.4%
$4.45
$1.31
▼
$9.30
$12.80M1.535,640 shs83,319 shs
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
$1.13
+6.6%
$1.38
$0.90
▼
$7.04
$43.20M2.0879,255 shs69,285 shs
InterCure Ltd. stock logo
INCR
InterCure
$3.60
-0.8%
$4.69
$3.12
▼
$7.55
$39.38M1.513,942 shs2,362 shs
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$14.50
-6.8%
$14.09
$5.75
▼
$23.30
$48.00M0.9469,753 shs26,981 shs
Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
0.00%0.00%+39.71%-10.53%-40.01%
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-4.50%-11.67%-13.11%-50.47%-80.97%
InterCure Ltd. stock logo
INCR
InterCure
-4.35%-0.14%-20.68%-23.92%-47.08%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.00%0.00%+9.85%+0.69%-14.96%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
2.25
Hold$8.3370.91% Upside
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
2.00
Hold$12.00961.95% Upside
InterCure Ltd. stock logo
INCR
InterCure
1.00
SellN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
2.00
Hold$42.00189.66% Upside

Current Analyst Ratings Breakdown

Latest ADIL, INM, DWTX, and INCR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/10/2026
InterCure Ltd. stock logo
INCR
InterCure
DowngradeSell (D-) ➝ Sell (E+)
11/9/2026
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
Initiated CoverageBuy$42.00
10/28/2026
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
UpgradeSell (E+) ➝ Sell (D-)
10/22/2026
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
Reiterated RatingSell (E+)
10/12/2026
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
DowngradeSell (D-) ➝ Sell (E+)
10/6/2026
InterCure Ltd. stock logo
INCR
InterCure
Reiterated RatingSell (D-)
9/24/2026
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
UpgradeSell (E+) ➝ Sell (D-)
9/9/2026
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
DowngradeSell (D-) ➝ Sell (E+)
9/2/2026
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
Reiterated RatingBuy
(Data available from 11/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/AN/AN/AN/A$4.75 per shareN/A
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/AN/AN/AN/A$1.68 per shareN/A
InterCure Ltd. stock logo
INCR
InterCure
$78.47M0.50N/AN/A$10.53 per share0.34
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
$4.94M9.72N/AN/A($0.36) per share-40.28
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
-$7.98M-$14.73N/AN/AN/AN/A-203.87%-512.41%11/18/2026 (Estimated)
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-$34.26M-$0.89N/AN/AN/AN/A-34.97%-29.50%N/A
InterCure Ltd. stock logo
INCR
InterCure
-$10.37MN/AN/AN/AN/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
-$12.56M-$1.64N/AN/AN/AN/A-282.17%-187.15%N/A

Latest ADIL, INM, DWTX, and INCR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/18/2026Q3 2026
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
-$0.1750N/AN/AN/AN/AN/A
11/5/2026Q3 2026
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
-$0.1550-$0.14+$0.0150-$0.14$0.10 million$0.10 million
9/9/2026Q4 2026
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/A-$12.43N/A-$12.4280N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/AN/AN/AN/AN/A
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/AN/AN/AN/AN/A
InterCure Ltd. stock logo
INCR
InterCure
N/AN/AN/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
N/A
5.63
5.63
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
N/A
2.78
3.89
InterCure Ltd. stock logo
INCR
InterCure
N/AN/AN/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
N/A
0.50
1.37

Institutional Ownership

CompanyInstitutional Ownership
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
16.41%
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
9.05%
InterCure Ltd. stock logo
INCR
InterCure
8.34%
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
20.12%

Insider Ownership

CompanyInsider Ownership
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
8.00%
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
0.30%
InterCure Ltd. stock logo
INCR
InterCure
N/A
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
0.85%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adial Pharmaceuticals, Inc. stock logo
ADIL
Adial Pharmaceuticals
202.63 million2.42 millionNo Data
Dogwood Therapeutics, Inc stock logo
DWTX
Dogwood Therapeutics
838.23 million38.11 millionN/A
InterCure Ltd. stock logo
INCR
InterCure
28510.94 millionN/AOptionable
InMed Pharmaceuticals Inc. stock logo
INM
InMed Pharmaceuticals
63.31 million328,000Not Optionable

Recent News About These Companies

Guggenheim Begins Coverage on InMed Pharmaceuticals (NASDAQ:INM)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Adial Pharmaceuticals stock logo

Adial Pharmaceuticals NASDAQ:ADIL

$4.88 -0.17 (-3.45%)
Closing price 10/28/2026
Extended Trading
$4.88 0.00 (0.00%)
As of 10/28/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Dogwood Therapeutics stock logo

Dogwood Therapeutics NASDAQ:DWTX

$1.13 +0.07 (+6.60%)
As of 12:48 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.

InterCure stock logo

InterCure NASDAQ:INCR

$3.63 0.00 (-0.03%)
As of 12:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

InMed Pharmaceuticals stock logo

InMed Pharmaceuticals NASDAQ:INM

$14.50 -1.06 (-6.81%)
Closing price 11/6/2026
Extended Trading
$14.50 0.00 (0.00%)
As of 11/6/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.